Developer docs
API playgroundTry for free, no card

Search company profiles

Enzyme

Full company profile

uuid0000xu9

Namestring
Enzyme
Legal namestring
Enzyme Corporation
Websiteurl
enzyme.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Enzyme (Enzyme Corporation) is a cloud-based electronic Quality Management System (eQMS) software company serving FDA-regulated life sciences organizations, specifically medical device, digital health, and biopharma companies. Founded in 2017 by Jared Seehafer and Jacob Graham and headquartered in South San Francisco, Enzyme was acquired by Greenlight Guru in July 2025, after which co-founder and CEO Jared Seehafer departed. The company operates as a brand under Greenlight Guru, a competing medical device eQMS provider with 1,000+ customers.

The company's core product, Enzyme QMS, is a 21 CFR Part 11 compliant SaaS platform, validated out-of-box and hosted on AWS with isolated Virtual Private Cloud environments per customer, TLS 1.2/1.3 encryption, and SSO support. The platform is structured into modules spanning the full product lifecycle — premarket activities (document control, change control, design control, risk management, suppliers, training) and postmarket activities (audits, complaints, nonconformance, CAPA). Enzyme emphasizes integration breadth with 70+ connections including Microsoft Office 365, Jira, GitHub, GitLab, Bitbucket, CircleCI, Jenkins, Salesforce, Slack, Okta, Zendesk, and Google Workspace, positioning the product to fit into existing customer workflows rather than forcing process changes. The company also achieved SOC 2 Type II certification in 2023 under AICPA standards.

Enzyme generates revenue through subscription-based licensing of its QMS software using an enterprise field sales motion with demo-based conversion as the primary engagement mechanism, supplemented by regulatory and quality consulting services. The customer base skews toward early-stage medical device and digital health startups (named logos include Endpoint Health/formerly GeneWEAVE, Subtle Medical, DawnLight Technologies, ClearCam, and Caption Health), with the platform positioned to scale with customers from startup through IPO. Disclosed funding is limited to approximately $1.97 million across a 2017 Y Combinator investment ($120K) and a 2017 seed round ($1.85M from DCVC, Hack VC, Parcel B, Refactor, Rock Health Capital, and Soma Capital), suggesting a capital-efficient or partially bootstrapped operating history prior to the July 2025 acquisition.

Short descriptiontext

Enzyme Corporation is a cloud-based electronic Quality Management System (eQMS) software company serving FDA-regulated medical device, digital health, and biopharma companies. Founded in 2017, it was acquired by Greenlight Guru in July 2025 and now operates as a brand under its acquirer.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
quality management software, life sciences compliance, FDA regulatory software, medical device QMS, electronic quality management
Industry4 codes
PRIMARYHLAGAJAI
Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAK
Laboratory Quality & GLP/GCLP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1QMS Software Subscription
TypeSubscription Recurring
Description

Enzyme generates revenue through subscription-based licensing of their electronic Quality Management System (eQMS) software. The platform is sold as a cloud-based SaaS solution supporting medical device, digital health, and biopharma companies with their quality and regulatory compliance needs.

enzyme.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Enzyme sells a cloud-based electronic Quality Management System (eQMS) software platform, branded as Enzyme QMS, that helps medical device, digital health, and biopharma companies manage FDA-regulated quality processes across the full product lifecycle from premarket to postmarket. The platform covers document control, change control, training, design control, risk management, suppliers, audits, complaints, nonconformance, and CAPA, and is delivered as a subscription-based SaaS product hosted on AWS with 21 CFR Part 11 compliance and 70+ third-party integrations. Enzyme also offers regulatory and quality consulting services to complement the software.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Enzyme offers a unified QMS software platform called Enzyme QMS (Electronic Quality Management System) designed for medical device, digital health, and biopharma companies. The platform consists of a core QMS product with integrated modules covering both premarket activities (Document Control, Change Control, Training, Design Control, Risk Management, Suppliers) and postmarket activities (Audits, Complaints, Nonconformance, CAPA). The platform is 21 CFR Part 11 compliant, validated out-of-box, and offers an industry-leading number of integrations. Enzyme also provides complementary consulting services for regulatory strategy and submission support.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-03
Description

Greenlight Guru acquired Enzyme to bolster innovation and customer support in the electronic quality management systems space for medical device companies. Greenlight Guru is a provider of electronic QMS for the medical device industry. The acquisition is intended to enhance product development and regulatory compliance, combining Enzyme's modern QMS platform with Greenlight Guru's operational strength and customer base of 1,000+ companies. Enzyme co-founder Jared Seehafer departed as CEO following the acquisition in July 2025.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Electronic QMS provider purpose-built for medical device companies; acquired Enzyme in July 2025. Directly comparable on core eQMS functionality, target customer (medical device, digital health), and FDA 21 CFR Part 11 / ISO 13485 positioning.

TypeDirect peer
Description

Long-standing eQMS suite for life sciences covering document, change, training, CAPA, audit, and validation. Comparable core product and regulated buyer base, with a broader enterprise footprint and longer sales cycles.

TypeDirect peer
Description

eQMS solution focused on life sciences quality and compliance on Salesforce. Comparable on regulated-vertical focus and cloud-native delivery, with overlap in document/change/CAPA workflows.

TypeBroad incumbent
Description

Large life-sciences cloud platform with Vault QualityDocs, Vault QMS, and Vault Training. Comparable QMS functionality bundled into a much broader regulated RIM/clinical suite serving enterprise pharma and med-device customers.

TypeEmerging player
Description

Mid-market QMS provider with regulated-industry focus including life sciences. Overlaps with Enzyme on document, change, CAPA, and audit modules for similar-size regulated customers.

TypeBroad incumbent
Description

TrackWise QMS for life sciences and other regulated industries. Comparable on core QMS workflows and regulated-vertical focus; a much larger installed enterprise base, including pharma and medical device manufacturers.

TypeBroad incumbent
Description

Enterprise QMS platform within Hexagon's quality and EHS portfolio. Comparable document, change, audit, and CAPA functionality, but positioned at larger enterprise accounts and broader industrial verticals.

TypeDirect peer
Description

Next-generation QMS built natively on the Salesforce platform with life-sciences, medical-device, and manufacturing verticals. Comparable cloud-native QMS positioning and enterprise field-sales GTM.

TypeDirect peer
Description

ISO 13485-compliant eQMS for medical device and life sciences companies of similar size to Enzyme. Directly comparable on customer segment, validation posture, and SaaS-only delivery.

TypeDirect peer
Description

Cloud eQMS for life sciences startups and mid-market companies. Closely comparable on target customer profile (medical device, pharma startups), GxP validation, and SaaS delivery model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration15 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enzyme Corporation is a cloud-based electronic Quality Management System (eQMS) software company serving FDA-regulated medical device, digital health, and biopharma companies. Founded in 2017, it was acquired by Greenlight Guru in July 2025 and now operates as a brand under its acquirer.

What Enzyme does

Enzyme (Enzyme Corporation) is a cloud-based electronic Quality Management System (eQMS) software company serving FDA-regulated life sciences organizations, specifically medical device, digital health, and biopharma companies. Founded in 2017 by Jared Seehafer and Jacob Graham and headquartered in South San Francisco, Enzyme was acquired by Greenlight Guru in July 2025, after which co-founder and CEO Jared Seehafer departed. The company operates as a brand under Greenlight Guru, a competing medical device eQMS provider with 1,000+ customers.

The company's core product, Enzyme QMS, is a 21 CFR Part 11 compliant SaaS platform, validated out-of-box and hosted on AWS with isolated Virtual Private Cloud environments per customer, TLS 1.2/1.3 encryption, and SSO support. The platform is structured into modules spanning the full product lifecycle — premarket activities (document control, change control, design control, risk management, suppliers, training) and postmarket activities (audits, complaints, nonconformance, CAPA). Enzyme emphasizes integration breadth with 70+ connections including Microsoft Office 365, Jira, GitHub, GitLab, Bitbucket, CircleCI, Jenkins, Salesforce, Slack, Okta, Zendesk, and Google Workspace, positioning the product to fit into existing customer workflows rather than forcing process changes. The company also achieved SOC 2 Type II certification in 2023 under AICPA standards.

Enzyme generates revenue through subscription-based licensing of its QMS software using an enterprise field sales motion with demo-based conversion as the primary engagement mechanism, supplemented by regulatory and quality consulting services. The customer base skews toward early-stage medical device and digital health startups (named logos include Endpoint Health/formerly GeneWEAVE, Subtle Medical, DawnLight Technologies, ClearCam, and Caption Health), with the platform positioned to scale with customers from startup through IPO. Disclosed funding is limited to approximately $1.97 million across a 2017 Y Combinator investment ($120K) and a 2017 seed round ($1.85M from DCVC, Hack VC, Parcel B, Refactor, Rock Health Capital, and Soma Capital), suggesting a capital-efficient or partially bootstrapped operating history prior to the July 2025 acquisition.

Enzyme firmographics

Firmographics
Name
Enzyme
Legal name
Enzyme Corporation
Website
https://enzyme.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Enzyme Corporation is a cloud-based electronic Quality Management System (eQMS) software company serving FDA-regulated medical device, digital health, and biopharma companies. Founded in 2017, it was acquired by Greenlight Guru in July 2025 and now operates as a brand under its acquirer.
Ownership category
akta.pro rank

Enzyme industry classification

Industry
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAI
Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAK
Laboratory Quality & GLP/GCLP Compliance
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGAKAL
Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Quality management software
  • Life sciences compliance
  • FDA regulatory software
  • Medical device QMS
  • Electronic quality management

Where Enzyme is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Enzyme business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. QMS Software Subscription: Enzyme generates revenue through subscription-based licensing of their electronic Quality Management System (eQMS) software. The platform is sold as a cloud-based SaaS solution supporting medical device, digital health, and biopharma companies with their quality and regulatory compliance needs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Enzyme product offering

Product offering

Core offering

Enzyme sells a cloud-based electronic Quality Management System (eQMS) software platform, branded as Enzyme QMS, that helps medical device, digital health, and biopharma companies manage FDA-regulated quality processes across the full product lifecycle from premarket to postmarket. The platform covers document control, change control, training, design control, risk management, suppliers, audits, complaints, nonconformance, and CAPA, and is delivered as a subscription-based SaaS product hosted on AWS with 21 CFR Part 11 compliance and 70+ third-party integrations. Enzyme also offers regulatory and quality consulting services to complement the software.

Product overview

Enzyme offers a unified QMS software platform called Enzyme QMS (Electronic Quality Management System) designed for medical device, digital health, and biopharma companies. The platform consists of a core QMS product with integrated modules covering both premarket activities (Document Control, Change Control, Training, Design Control, Risk Management, Suppliers) and postmarket activities (Audits, Complaints, Nonconformance, CAPA). The platform is 21 CFR Part 11 compliant, validated out-of-box, and offers an industry-leading number of integrations. Enzyme also provides complementary consulting services for regulatory strategy and submission support.

Differentiator

Problem solved

Functional benefit

Companies that use Enzyme

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Enzyme technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration15 records

Feature5 records

Enzyme partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Greenlight GurucoreStrategic or Co-development Partner · 3 August 2025Greenlight Guru acquired Enzyme to bolster innovation and customer support in the electronic quality management systems space for medical device companies. Greenlight Guru is a provider of electronic QMS for the medical device industry. The acquisition is intended to enhance product development and regulatory compliance, combining Enzyme's modern QMS platform with Greenlight Guru's operational strength and customer base of 1,000+ companies. Enzyme co-founder Jared Seehafer departed as CEO following the acquisition in July 2025.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Enzyme competitors and assessment

Company assessment

Direct peers

  • Greenlight Guru: Electronic QMS provider purpose-built for medical device companies; acquired Enzyme in July 2025. Directly comparable on core eQMS functionality, target customer (medical device, digital health), and FDA 21 CFR Part 11 / ISO 13485 positioning.
  • MasterControl: Long-standing eQMS suite for life sciences covering document, change, training, CAPA, audit, and validation. Comparable core product and regulated buyer base, with a broader enterprise footprint and longer sales cycles.
  • Dot Compliance: eQMS solution focused on life sciences quality and compliance on Salesforce. Comparable on regulated-vertical focus and cloud-native delivery, with overlap in document/change/CAPA workflows.
  • ComplianceQuest: Next-generation QMS built natively on the Salesforce platform with life-sciences, medical-device, and manufacturing verticals. Comparable cloud-native QMS positioning and enterprise field-sales GTM.
  • SimplerQMS: ISO 13485-compliant eQMS for medical device and life sciences companies of similar size to Enzyme. Directly comparable on customer segment, validation posture, and SaaS-only delivery.
  • Qualio: Cloud eQMS for life sciences startups and mid-market companies. Closely comparable on target customer profile (medical device, pharma startups), GxP validation, and SaaS delivery model.

Broad incumbents

  • Veeva Systems: Large life-sciences cloud platform with Vault QualityDocs, Vault QMS, and Vault Training. Comparable QMS functionality bundled into a much broader regulated RIM/clinical suite serving enterprise pharma and med-device customers.
  • Sparta Systems (TrackWise): TrackWise QMS for life sciences and other regulated industries. Comparable on core QMS workflows and regulated-vertical focus; a much larger installed enterprise base, including pharma and medical device manufacturers.
  • ETQ (Hexagon): Enterprise QMS platform within Hexagon's quality and EHS portfolio. Comparable document, change, audit, and CAPA functionality, but positioned at larger enterprise accounts and broader industrial verticals.

Emerging players

  • AssurX: Mid-market QMS provider with regulated-industry focus including life sciences. Overlaps with Enzyme on document, change, CAPA, and audit modules for similar-size regulated customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Enzyme social profiles

Digital presence

Enzyme compliance and trust

Trust signal

Compliance2 records

Enzyme financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enzyme leadership team

Management profile

Number of profiles

Profiles2 records

Enzyme funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enzyme M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enzyme

What does Enzyme do?

Enzyme sells a cloud-based electronic Quality Management System (eQMS) software platform, branded as Enzyme QMS, that helps medical device, digital health, and biopharma companies manage FDA-regulated quality processes across the full product lifecycle from premarket to postmarket. The platform covers document control, change control, training, design control, risk management, suppliers, audits, complaints, nonconformance, and CAPA, and is delivered as a subscription-based SaaS product hosted on AWS with 21 CFR Part 11 compliance and 70+ third-party integrations. Enzyme also offers regulatory and quality consulting services to complement the software.

Is Enzyme a public or private company?

Enzyme is a private company. It is currently acquired.

When was Enzyme founded?

Enzyme was founded in 2017. It employs 11 to 50 people.

Where is Enzyme based?

Enzyme is headquartered in South San Francisco, United States, in the North America region.

How does Enzyme make money?

One revenue line is on record: QMS Software Subscription.

Who are Enzyme's main competitors?

Direct peers on record are Greenlight Guru, MasterControl, Dot Compliance, ComplianceQuest, SimplerQMS and Qualio. Broad incumbents are Veeva Systems, Sparta Systems (TrackWise) and ETQ (Hexagon). AssurX is listed as an emerging player.

Does Enzyme have an API?

No public API is recorded for Enzyme.

What industry is Enzyme in?

Its primary akta.pro industry code is HLAGAJAI, Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Growth Patterns Driving Rapid Expansion in the Healthcare Quality Management Software MarketThe healthcare quality management software market is projected to grow from approximately $1.77 billion to $3.32 billion by 2030, representing a compound annual growth rate of 13.9%, driven by AI-powered quality insights, cloud-native solutions, remote monitoring, and increased investments in healthcare analytics. In July 2025, US-based Greenlight Guru acquired Enzyme to strengthen its position in medical device quality management software, while in March 2025, SS Innovations International launched India's first Mobile Tele-Surgical Unit equipped with the SSI Mantra Surgical Robot to bring robotic surgery to underserved regions.The Times of IndiaEnzyme Office Spaces signs 3.5 lakh sq ft in Bengaluru, expands footprint - The Economic TimesEnzyme Office Spaces has signed lease agreements for 3.5 lakh square feet of office space in Bengaluru, expanding its presence across Whitefield, HSR Layout, and Hebbal micro-markets. The new centres will add approximately 5,000 seats and are expected to contribute about Rs 50 crore in annual revenue. The company currently manages 2 million sq ft across India and plans to add another 2–2.5 lakh sq ft through new lease agreements in the next financial year, driven by demand for flexible workspaces.CB InsightsProducts, Competitors, Financials, Employees, Headquarters LocationsThe article reports on the merger of Ultralight Labs into Greenlight Guru, a provider of electronic quality management systems for the medical device industry, intended to enhance product development and regulatory compliance. Additionally, Greenlight Guru acquired Enzyme to bolster innovation and customer support.PR NewswireGreenlight Guru Acquires Enzyme to Power Ongoing Innovation and Strengthen Customer SupportGreenlight Guru, a leading provider of software solutions for the medical device lifecycle, announced the acquisition of Enzyme, a modern quality management system (QMS) company for life sciences organizations, on July 24, 2025. The acquisition follows Enzyme CEO and Co-founder Jared Seehafer's decision to transition to a new career path, seeking a trusted home for the company's customers. This marks Greenlight Guru's second acquisition in recent weeks, following its purchase of MedTech startup Ultralight Labs last month, as part of its broader strategy to expand its platform offerings for medtech and life sciences innovators.Greenlight GuruGreenlight Guru Acquires EnzymeGreenlight Guru acquired Enzyme, a quality management system company for life sciences, on July 23, 2025. The deal follows Enzyme CEO Jared Seehafer's decision to transition, and Greenlight Guru is working with Enzyme's customers to ensure continuity. This is the second acquisition in recent weeks, following Ultralight Labs.Food Business NewsEnzyme benefits the focus of symposiumAmano Enzyme USA and the University of Minnesota will sponsor an enzyme technology symposium on May 5 at the McNamara Alumni Center in Minneapolis. The event will feature academic and industry speakers from North America and Japan, focusing on enzymes' role in sustainability and economic benefits. Amano hopes to make it a regular event.PR NewswireNicolle Cannon to Host Quarterly Webinar Series on Electronic Quality Management SystemsCannon Quality Group (CQG) announced that its CEO and founder Nicolle Cannon will host a quarterly webinar series on the selection and implementation of electronic quality management systems (eQMS) for the medical device, Medtech, life sciences, biotech, and IVD industries, with the first episode featuring Enzyme on March 11, 2021. The company reports a growing shift in 2021 toward eQMS adoption as quality management professionals move away from paper-based systems earlier in their operations. Subsequent episodes will continue featuring other leading eQMS solution providers.TechCrunchEnzyme.com wants to make FDA compliance easier for startupsEnzyme.com, a YC-backed startup, launched automated software to help health startups navigate FDA compliance, aiming to reduce paperwork. It raised $1.85 million and works with about 10 companies, targeting early-funded digital health firms. The company plans aggressive growth in 2018.